[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:tp53-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","TP53 Gene",7,[8,16,22,28,35,41,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04855695","Avo In R\u002FR And Previously Untreated MCL",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:46.948970Z","2026-05-05T02:47:14.265444Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05861050","Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.958425Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[12],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[32],"Phase 2","2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",[32],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:27.422581Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[45],"Phase 1","2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z"]